N4 Pharma PLC Grant of options (0390C)
26 September 2018 - 2:48PM
UK Regulatory
TIDMN4P
RNS Number : 0390C
N4 Pharma PLC
26 September 2018
26 September 2018
N4 Pharma Plc
("N4 Pharma" or the "Company")
Grant of options
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company,
announces that the Company has today granted a total of 1,004,000
options over ordinary shares in the Company ("Ordinary Shares") to
certain members of senior management pursuant to the Company's
unapproved share options scheme (the "Options"). The Options have
been granted as follows:
Total number
Options over of options
Ordinary over Ordinary
Shares previously Number of Shares now
Name held Options granted held
Allen Hey, Head of CMC Program
Development, Biologics 0 717,143 717,143
Andrew Leishman, Head of
Nuvec Development 0 286,857 286,857
The Options have an exercise price of 6.60p, which was the
closing mid-market price of an Ordinary Share in the Company on 25
September 2018, being the day prior to the grant, and can be
exercised from three years up until ten years from the date of
grant. Following this grant of Options, there are a total of
7,249,084 options outstanding over Ordinary Shares and 11,054,071
warrants outstanding over Ordinary Shares.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Allen William Hey
-------------------------- --------------------------------------------
2 Reason for the notification
------------------------------------------------------------------------
a) Position/status Head of CMC Program Development, Biologics,
a PDMR
-------------------------- --------------------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------- --------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------------
a) Name N4 Pharma plc
-------------------------- --------------------------------------------
b) LEI 213800OIN8T68PM7HK77
-------------------------- --------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
------------------------------------------------------------------------
a) Description of the Ordinary shares of 0.4p each in N4 Pharma
financial instrument, PLC
type of instrument
Identification code Identification code (ISIN) for N4 Pharma
PLC ordinary shares:
GB00BYW8QM32
-------------------------- --------------------------------------------
b) Nature of the transaction Grant of options
-------------------------- --------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
Exercise
price of
6.6p 717,143
----------
-------------------------- --------------------------------------------
d) Aggregated information
- Aggregated volume n/a
- Price
-------------------------- --------------------------------------------
e) Date of the transaction 26 September 2018
-------------------------- --------------------------------------------
f) Place of the transaction Outside a trading venue
-------------------------- --------------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Andrew Leishman
-------------------------- ------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------
a) Position/status Head of Nuvec Development, a PDMR
-------------------------- ------------------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------- ------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------
a) Name N4 Pharma plc
-------------------------- ------------------------------------------
b) LEI 213800OIN8T68PM7HK77
-------------------------- ------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------
a) Description of the Ordinary shares of 0.4p each in N4 Pharma
financial instrument, PLC
type of instrument
Identification code Identification code (ISIN) for N4 Pharma
PLC ordinary shares:
GB00BYW8QM32
-------------------------- ------------------------------------------
b) Nature of the transaction Grant of options
-------------------------- ------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
Exercise
price of
6.6p 286,857
----------
-------------------------- ------------------------------------------
d) Aggregated information
- Aggregated volume n/a
- Price
-------------------------- ------------------------------------------
e) Date of the transaction 26 September 2018
-------------------------- ------------------------------------------
f) Place of the transaction Outside a trading venue
-------------------------- ------------------------------------------
Enquiries:
N4 Pharma Plc
Nigel Theobald, CEO Via Alma PR
Allenby Capital Limited Tel: +44(0)203 328 5656
James Reeve/Virginia Bull/Asha Chotai
Alma PR
Josh Royston Tel: +44(0)778 090 1979
Robyn Fisher Tel: +44(0)754 070 6191
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHLFMTTMBITBFP
(END) Dow Jones Newswires
September 26, 2018 08:48 ET (12:48 GMT)
N4 Pharma (LSE:N4P)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
N4 Pharma (LSE:N4P)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
